As part of a major breakthrough a distinguished group of researchers hailing from Canada have come out with the finding of, for the first time in the recorded history, the human embryonic stem cells, better known as hESC possess the exclusive capability in the generation of hESC-derived fibroblast-like niche cells or the hdFs in vitro regardless of the elimination from the vivo microenvironment. It has been further confirmed by the researchers that the human embryonic stem cells are able to make available an incessant supply of proteins that tend to be supportive, which in turn is comprised of insulin-like growth factor 2 (IGF-II), that according to the researchers, from this time on show could be "the" protein for the continuance of the hESCs. In other words, human embryonic stem cells are perpetual machines that generate fuel for life.

It is to be noted in this respect, that prior to this there was a general consideration that stem cells used to be directly influenced by cells in the local environment or "niche," but the more investigative researches in this aspect have ascertained that the state of affairs may be more complex. The present article, a fine exposition of earnest effort through the writings of eminent scientific director Mick Bhatia and colleagues from the McMaster Cancer and Stem Cell Research Institute confirm on the other hand that the human embryonic stem or ES cells are in reality able to produce characteristic niche cells. They are also found in due course to release stem-cell nourishing proteins so as to facilitate their "parents" ticking over.

Moreover, while talking to the concerned persons of the research team it has been revealed that this sensational approach, as expected considered as success according to their consideration, have expressed the immense interest of the researchers in the identification of a relationship between stem cells and their slow but sure function. The prime reason behind this huge interest being, the niche becomes a symbol of a specified route for the modification of the stem cell behavior. What's more, to them, if human ES cells by the virtue of an effective guidance can be guided down through a consistent but a meticulous conduit, then there happens to be fair chance of the better uses of those in respect of clinical therapy in the near future for the regeneration of damaged tissue that includes neurons for Parkinson's disease, or insulin producing cells for diabetes.

Dr. Mick Bhatia when requested to speak on this behalf said,  "This will be critical for future developments involving drug and gene screening of human ES cells, that will be required before clinical use of human stem cells of this kind."